Related Experiment Videos
Evaluating prethrombotic state in lung cancer using molecular markers
E C Gabazza1, O Taguchi, T Yamakami
1Third Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Japan.
Chest
|January 1, 1993
Summary
Lung cancer patients show elevated blood markers for clotting and fibrinolysis, even in early stages. These molecular markers, including D-dimer fragments and thrombin-antithrombin III complex, indicate subclinical activation of coagulation.
Area of Science:
- Oncology
- Hematology
- Biochemistry
Background:
- Malignant diseases frequently cause clotting abnormalities.
- Molecular markers of hemostasis offer sensitive detection of coagulation activation.
Purpose of the Study:
- To assess subclinical hemostasis activation in lung cancer patients using novel molecular markers.
- To correlate marker levels with disease extent, metastasis, histology, and chemotherapy response.
Main Methods:
- Measured thrombin-antithrombin III complex (TAT), D-dimer fragments (DD), and plasmin-alpha 2-antiplasmin complex (PIC) in 58 lung cancer patients.
- Compared marker levels to healthy controls and patients with chronic obstructive pulmonary disease (COPD).
Main Results:
- Lung cancer patients exhibited significantly elevated DD, PIC, and TAT levels compared to controls and COPD patients.
- Higher marker levels were observed in patients with extensive disease and distant metastasis.
- Subclinical activation of blood coagulation and fibrinolysis was evident even in early lung cancer stages.
Conclusions:
- Molecular markers of hemostasis are significantly elevated in lung cancer patients.
- These markers indicate early, subclinical activation of coagulation and fibrinolysis in lung cancer.
- Clotting activation levels may vary by tumor histology and treatment response.